Enhance your nephrology practice with CME and tools focused on kidney medicine.
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
Improving Sleep and Mental Health in Patients with CKD-aP
Kappa-Opioid Settings: Real-World Evidence Insights
CKD-aP Treatment Tool Kit
Quantifying CKD-aP: Tools for Better Care
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD
Dana Rizk, MD
Potassium Binders in Practice: Clinical Trial Evidence
Ellie Kelepouris, MD, FACP, FAHA
Patrick Rossignol, MD, PhD
Elevating CKD-aP Care: New Frontier
The Critical Interplay: CKD, HF, and HyperkaleAmia
Javed Butler, MD
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF
Potassium Binders: Safety Comes First!
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Jonathan Barratt, MD, PhD
Sydney Tang, MBBS, MD
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Stefan D. Anker, MD, PhD
Mahir Karakas, MD, PhD, MBA
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD
Muh Geot Wong, MBBS, PhD
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Robert J. Mentz, MD, FHFSA, FACC
Piotr Ponikowski, MD, PhD, FESC, FHFA
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
KALMing the Itch: Improving QoL in Patients with CKD-aP
Joel Topf, MD
Kieran McCafferty, MD
Separating Fact from Fiction: The Realities of CKD-aP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Antoine Lanot, MD, PhD
Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease
Mario Cozzolino, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.